跳到正文
原文
Nature Medicine· Lekha Mikkilineni·· 1 天前AI 评分51

BCMA CAR-T细胞治疗相关肠结肠炎多中心研究显示仅32%患者获得缓解

Multicenter characterization of enterocolitis associated with BCMA-directed CAR T cell therapy

AI 导读

一项发表于Nature Medicine的多中心病例系列研究报道了BCMA定向CAR T细胞治疗后免疫效应细胞相关肠结肠炎的临床特征。研究纳入89例接受BCMA CAR-T治疗的患者,其中66例(约74%)发生该并发症;最后随访时仅32%的患者达到疾病缓解,13例死亡被直接归因于此并发症的严重后果。

正文

Nature Medicine, Published online: 19 November 2026; doi:10.1038/s41591-026-04783-y

In a large multicenter case series, only 32% of patients who developed immune effector cell-associated enterocolitis following treatment with BCMA-directed CAR T cells had achieved disease resolution at last follow-up, with some deaths directly attributable to complications of this disorder.

来源:Nature Medicine · nature.com